You are here

Article Text

Article menu
Download PDFPDF
Online articles
Systematic review with meta-analysis
Metformin may not reduce cardiovascular risk or all-cause mortality
  1. Matteo Monami
  1. Correspondence to: Matteo Monami
    Department of Cardiovascular Medicine, Section of Diabetes, Cardiovascular and Geriatric Medicine, University of Florence and Careggi Teaching Hospital, Via delle Oblate 4, Florence 50141, Italy; mmonami{at}libero.it

https://doi.org/10.1136/eb-2012-100836

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Boussageon R, Supper I, Bejan-Angoulvant T, et al. Reappraisal of metformin efficacy in the treatment of Type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med 2012; 9: 268– 82.OpenUrl

    Context

    The treatment of hyperglycaemia is considered as one of the tools for preventing cardiovascular disease in Type 1 and Type 2 diabetic (T2D) patients.1 ,2 Metformin is recommended as the first-line drug for T2D by most international guidelines (IDF.2005. http://www.idf.org, 2007. http://www.aace.com, http://www.diabetesjournals.org, http://www.nice.org.uk/CG66). The preference for metformin over other available drugs is based on its efficacy on blood glucose control, tolerability, safety and low cost (IDF.2005. http://www.idf.org, 2007. http://www.aace.com, http://www.diabetesjournals.org, http://www.nice.org.uk/CG66). Metformin seems to have a favourable profile of action on several extraglycaemic risk factors, including lipids, …

    View Full Text

    Footnotes

    • Competing interests None.